BioRestorative Therapies
40 Marcus Drive
Suite one
Melville, Long Island
New York
11747
United States
Tel: 6317608405
Website: http://www.biorestorative.com/
Email: hr@BIORESTORATIVE.COM
149 articles about BioRestorative Therapies
-
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
4/16/2024
BioRestorative Therapies, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy candidate, in treating chronic lumbar disc disease (“cLDD”).
-
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
4/8/2024
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced a collaboration with Galen Patient Recruitment, Inc.
-
BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
4/3/2024
BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission.
-
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
4/1/2024
BioRestorative Therapies, Inc., a clinical stage company focused on stem cell-based therapies, announced the filing of its Form 10-K annual report with the Securities and Exchange Commission for the year ended December 31, 2023.
-
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
3/11/2024
BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced its participation in the 36th Annual ROTH Conference being held March 17-19, 2024 at the Ritz Carlton, Laguna Niguel in Dana Point, California
-
BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market
2/6/2024
BioRestorative Therapies, Inc. today announced it has entered into agreements with certain holders of its existing warrants exercisable for 3,351,580 shares of its common stock.
-
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
2/5/2024
BioRestorative Therapies, Inc today announced the public availability of a poster, presented yesterday at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, which describes preliminary 26 and 52 week blinded data from the ongoing Phase 2 clinical trial of the Company’s lead clinical candidate, BRTX-100, in subjects with chronic lumbar disc disease (“cLDD”).
-
BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting
2/1/2024
BioRestorative Therapies, Inc today announced that preliminary 26–52 week blinded data from the ongoing Phase 2 clinical trial of BRTX-100 in subjects with chronic lumbar disc disease (“cLDD”) will be presented by Francisco Silva, Vice President of Research and Development, at the Orthopaedic Research Society (ORS) 2024 Annual Meeting, taking place February 2-6, 2024 in Long Beach, California.
-
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
12/12/2023
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s metabolic ThermoStem® program.
-
BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City
10/9/2023
BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, announced today that Company CEO, Lance Alstodt, has been invited to present at the ROTH MKM Healthcare Opportunities Conference.
-
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
9/12/2023
BioRestorative Therapies, Inc . (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based therapies, today announced that it has entered into a supply agreement with Evolutionary Biologics, a supplier of biologic-based cosmetics.
-
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
9/8/2023
BioRestorative Therapies, Inc . today announced that Northwell Health, New York State's largest health care provider has been activated and can now start recruitment in the State of New York for BioRestorative’s ongoing Phase 2 clinical trial targeting chronic lumbar disc disease (“cLDD”).
-
Chronic Pain Specialist Speaks At Panel On Stem Cell-Based Therapies And The Need For Spinal Care Reform - Insights From The Discussion
7/31/2023
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to the National Institute of Neurological Disorders and Stroke, approximately 80% of adults will experience back pain at some point.
-
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
7/21/2023
BioRestorative Therapies Inc. has announced that it has been granted a license by the New York State Department of Health to operate as a tissue bank.
-
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
7/11/2023
BioRestorative Therapies, Inc. today announced it has entered into a definitive agreement with several accredited and institutional investors for the sale of 685,033 shares of the Company’s common stock at an offering price of $3.03 per share in a registered direct offering.
-
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
7/7/2023
BioRestorative Therapies Inc. (NASDAQ:BRTX) has received a unanimous recommendation to proceed in its Phase 2 clinical trial for chronic lumbar disc disease, BRTX-100.
-
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
6/27/2023
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX) today announced that the independent Data Safety Monitoring Board (“DSMB”), which is overseeing the Company’s ongoing Phase 2 clinical trial to treat chronic lumbar disc disease (“cLDD”), unanimously recommended the continuation of BioRestorative’s study in accordance with the current version of the protocol with no changes.
-
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
6/12/2023
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ: BRTX ) today announced that the final subject in its BRTX-100 Phase 2 clinical trial safety cohort has been dosed.
-
BioRestorative Therapies, Inc. to attend the Jefferies 2023 Healthcare Conference
6/1/2023
BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies, today announced that CEO Lance Alstodt will participate at the Jefferies Healthcare Conference being held June 7-9, 2023 at the Marriot Marquis in New York.
-
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
5/31/2023
BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX) today announced that it has received a license from the New York State Department of Health to act as a tissue bank for the processing of mesenchymal stem cells from autologous donors.